Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL

A. Campanella, A. Capasso, S. Heltai, C. Taccetti, E. Albi, Y. Herishanu, S. Haggenburg, T. Chatzikonstantinou, M. Doubek, M. Kättström, K. Giannopoulos, M. Simkovic, C. Moreno, M. Massaia, H. Bumbea, S. Alshemmari, P. Ranghetti, E. Perotta, F....

. 2024 ; 99 (4) : 745-750. [pub] 20240124

Jazyk angličtina Země Spojené státy americké

Typ dokumentu dopisy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006573

Grantová podpora
IBR-I-20-EMEA-014-V01/54179060CLL4024 Janssen
NOPRODCLL4001 Janssen
FNBr 65269705 MH CZ - DRO
ID 1852164 Fondazione Umberto Veronesi

Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006573
003      
CZ-PrNML
005      
20240423155350.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.27218 $2 doi
035    __
$a (PubMed)38264829
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Campanella, A $u Vita Salute San Raffaele University, Milan, Italy $u IRCCS San Raffaele Hospital, Milan, Italy $1 https://orcid.org/0000000234631199
245    10
$a Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL / $c A. Campanella, A. Capasso, S. Heltai, C. Taccetti, E. Albi, Y. Herishanu, S. Haggenburg, T. Chatzikonstantinou, M. Doubek, M. Kättström, K. Giannopoulos, M. Simkovic, C. Moreno, M. Massaia, H. Bumbea, S. Alshemmari, P. Ranghetti, E. Perotta, F. Martini, E. Sant'Antonio, M. Colia, C. Combi, S. Levi, AP. Kater, M. Hazenberg, IS. Nijhof, Q. Hofsink, C. Demosthenous, J. Kotaskova, J. Zaleska, F. Vrbacky, AM. Raya, D. Bisogno, IE. Tripoli, VM. Popov, V. Roman, N. Stavroyianni, M. Karypidou, E. Scarano, M. Locatelli, M. Frenquelli, L. Scarfò, K. Stamatopoulos, P. Ghia
520    9_
$a Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.
650    _2
$a lidé $7 D006801
650    _2
$a SARS-CoV-2 $7 D000086402
650    12
$a chronická lymfatická leukemie $x farmakoterapie $7 D015451
650    _2
$a vakcíny proti COVID-19 $7 D000086663
650    12
$a COVID-19 $7 D000086382
650    _2
$a protilátky $7 D000906
650    _2
$a receptor interleukinu-2 - alfa-podjednotka $7 D053645
650    _2
$a buněčná imunita $7 D007111
650    _2
$a protilátky virové $7 D000914
650    _2
$a vakcinace $7 D014611
655    _2
$a dopisy $7 D016422
700    1_
$a Capasso, A $u Vita Salute San Raffaele University, Milan, Italy $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Heltai, S $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Taccetti, C $u Vita Salute San Raffaele University, Milan, Italy $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Albi, E $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Herishanu, Y $u Tel Aviv Sourasky Medical Center, Tel Aviv, Israel $u Tel Aviv University, Tel-Aviv, Israel $1 https://orcid.org/0000000278640089
700    1_
$a Haggenburg, S $u Amsterdam UMC, Amsterdam, The Netherlands
700    1_
$a Chatzikonstantinou, T $u Centre for Research and Technology Hellas, Thessaloniki, Greece
700    1_
$a Doubek, M $u University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000212696282
700    1_
$a Kättström, M $u Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
700    1_
$a Giannopoulos, K $u Medical University of Lublin, Lublin, Poland $1 https://orcid.org/0000000301354030
700    1_
$a Simkovic, M $u 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
700    1_
$a Moreno, C $u Hospital de la Santa Creu I Sant Pau, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
700    1_
$a Massaia, M $u AO S.Croce e Carle, Cuneo, Italy $u Turin University, Turin, Italy
700    1_
$a Bumbea, H $u University Emergency Hospital, Bucharest, Romania $u University of Medicine and Pharmacy, Carol Davila, Bucharest, Romania
700    1_
$a Alshemmari, S $u Department of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait $1 https://orcid.org/0000000255975839
700    1_
$a Ranghetti, P $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Perotta, E $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Martini, F $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Sant'Antonio, E $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Colia, M $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Combi, C $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Levi, S $u Tel Aviv Sourasky Medical Center, Tel Aviv, Israel $1 https://orcid.org/0000000214539029
700    1_
$a Kater, A P $u Amsterdam UMC, Amsterdam, The Netherlands
700    1_
$a Hazenberg, M $u Amsterdam UMC, Amsterdam, The Netherlands
700    1_
$a Nijhof, I S $u Amsterdam UMC, Amsterdam, The Netherlands $u St Antonius Hospital, Nieuwegein, The Netherlands
700    1_
$a Hofsink, Q $u Amsterdam UMC, Amsterdam, The Netherlands
700    1_
$a Demosthenous, C $u Centre for Research and Technology Hellas, Thessaloniki, Greece $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
700    1_
$a Kotaskova, J $u University Hospital Brno, Brno, Czech Republic $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Zaleska, J $u Medical University of Lublin, Lublin, Poland
700    1_
$a Vrbacky, F $u 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
700    1_
$a Raya, A Mora $u Hospital de la Santa Creu I Sant Pau, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
700    1_
$a Bisogno, D $u AO S.Croce e Carle, Cuneo, Italy
700    1_
$a Tripoli, I E $u AO S.Croce e Carle, Cuneo, Italy $u Turin University, Turin, Italy
700    1_
$a Popov, V M $u Colentina Clinical Hospital, Bucharest, Romania
700    1_
$a Roman, V $u Center of Immunology Department, Stefan S. Nicolau Institute of Virology, Bucharest, Romania
700    1_
$a Stavroyianni, N $u Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
700    1_
$a Karypidou, M $u Centre for Research and Technology Hellas, Thessaloniki, Greece
700    1_
$a Scarano, E $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Locatelli, M $u Laboratory Medicine Service, IRCCS San Raffaele Hospital, Milano, Italy
700    1_
$a Frenquelli, M $u IRCCS San Raffaele Hospital, Milan, Italy
700    1_
$a Scarfò, L $u Vita Salute San Raffaele University, Milan, Italy $u IRCCS San Raffaele Hospital, Milan, Italy $1 https://orcid.org/0000000208440989
700    1_
$a Stamatopoulos, K $u Centre for Research and Technology Hellas, Thessaloniki, Greece
700    1_
$a Ghia, P $u Vita Salute San Raffaele University, Milan, Italy $u IRCCS San Raffaele Hospital, Milan, Italy
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 99, č. 4 (2024), s. 745-750
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38264829 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155347 $b ABA008
999    __
$a ok $b bmc $g 2080897 $s 1216340
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 99 $c 4 $d 745-750 $e 20240124 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$a IBR-I-20-EMEA-014-V01/54179060CLL4024 $p Janssen
GRA    __
$a NOPRODCLL4001 $p Janssen
GRA    __
$a FNBr 65269705 $p MH CZ - DRO
GRA    __
$a ID 1852164 $p Fondazione Umberto Veronesi
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace